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Abstract
Background: It has been reported that some single-nucleotide polymorphisms (SNPs) in lipid regulators such as
apolipoproteins and cell surface molecules for hepatitis C virus (HCV) entry into hepatocytes are associated with
HCV infection. However, it is unknown how HCV infection is affected by altered lipid metabolism resulting from
the SNPs. We investigated the relationship between these SNPs and HCV infection status, and also analyzed the
mechanism by which these SNPs mediate HCV infection via lipid metabolism alterations.
Methods: Serum lipid and apolipoprotein profiles were tested in 158 HCV-positive and 220 HCV-negative subjects.
We selected 22 SNPs in five lipid regulator genes which were related to HCV entry into hepatocytes and to lipid
metabolism (APOA1, APOB, SR-B1, LDLR, and APOE), and their polymorphisms were analyzed using the PCR-sequence-
specific oligonucleotide probe-Luminex method.
Results: An APOB N4311S (g.41553a > g) SNP, rs1042034, was significantly associated with HCV positivity; the HCV
positivity rate for the minor allele AA genotype was significantly higher than for genotype AG + GG (P = 0.016). Other
SNPs except for APOB P2712L SNP rs676210, which is in linkage disequilibrium with rs1042034, showed no significant
difference in genotype distribution. The serum level of low density lipoprotein-cholesterol (LDL-C) in the genotype AA
group was significantly lower than in the genotype non-AA group (P = 0.032), whereas the triglyceride (TG) level was
significantly higher (P = 0.007).
Conclusion: An APOB SNP, rs1042034, is closely associated with HCV infection through lipid metabolism alteration. The
minor allele AA genotype might contribute to facilitating serum LDL uptake into hepatocytes via LDLR by modifying
their affinity and interaction and may have an influence on HCV infection by their entry to the liver through the LDLR.
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Background
Hepatitis C virus (HCV) infects approximately 185 million
people worldwide [1]. HCV infection typically causes
chronic liver disease and can lead to liver cirrhosis and
hepatocellular carcinoma (HCC) [2]. Accumulating stud-
ies have revealed that the HCV life cycle is closely associ-
ated with host lipid metabolism.
It has been reported that HCV entry into hepatocytes
occurs through cell surface molecules such as low
density lipoprotein receptor (LDLR), scavenger receptor
class B type 1 (SR-B1), claudin-1 (CLDN1), DC-SIGN,
L-SIGN, and CD81. However, the details of the under-
lying mechanisms have not yet been clarified [3]. Among
these molecules LDLR and SR-B1 also play a crucial role
in lipid metabolism. Apolipoproteins are proteins on the
surface of lipoprotein particles and stabilize the structure
of lipoproteins. Apolipoprotein B (APOB) is one of the
major apolipoproteins and it transfers lipoproteins such
as chylomicron, very low density lipoprotein (VLDL),
* Correspondence: takayama@tokushima-u.ac.jp
1Department of Gastroenterology and Oncology, Tokushima University
Graduate School of Biomedical Sciences, 3-18-15, Kuramoto-cho, Tokushima
770-8503, Japan
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Harada et al. BMC Gastroenterology  (2018) 18:24 
DOI 10.1186/s12876-018-0747-5
and low density lipoprotein (LDL) as a carrier. It is
secreted from the liver as a component of the outer sur-
face of VLDL particles, which are also produced in the
liver, and circulates in blood, irreversibly associating with
VLDL and LDL. APOB-100 serves as a ligand for LDLRs
on the cell membrane of hepatocytes. Thus, the LDL
particle enters into hepatocyte through the LDLR [4–6].
In the HCV life cycle, HCV replication begins in a
membranous web on the endoplasmic reticulum
membrane in hepatocytes, where VLDL assembly also
occurs. Both HCV particles and VLDL particles are
secreted from hepatocytes and circulate in blood as a
complex referred to as a lipo-viral particle (LVP). Fur-
thermore, APOB-100 and apolipoprotein E (APOE),
which are referred to as VLDL-associated proteins,
are present on the surface of the complex. They form
LVP with HCV particles, indicating that they are
deeply involved in the formation of infectious HCV
particles [7]. After circulation in the blood, infectious
HCV particles enter into hepatocytes with LDL
through the LDLR [8].
It is well known that apolipoproteins and cell surface
molecules such as LDLR and SR-B1 have single-
nucleotide polymorphisms (SNPs), and some of the
SNPs cause lipid metabolism disorders, leading to a high
risk of cardiovascular events [9–11]. Regarding the asso-
ciation with HCV, several studies have suggested that
SNPs of these lipid-metabolic regulators correlate with
HCV infection; e.g., an SNP in LDLR exon 13 (rs5925) is
associated with susceptibility to HCV infection [12]; an
SNP in LDLR exon8 (rs11669576) is associated with se-
verity of hepatic fibrosis; and an SNP in LDLR exon10
(rs5930) is associated with viral clearance and overall in-
flammation of the liver [13]. SNPs in LDLR 3’UTR re-
gion (rs1433099) and intron 14 (rs2569540) have been
reported to have an association with hepatitis C viral
load in the pre-treatment state [14]. Furthermore, poly-
morphisms of APOE have been reported to be associated
with persistent HCV infection and the degree of liver
damage [15, 16].
Thus, it is assumed that SNPs of lipid regulators have
a strict association with HCV infection and lipid metab-
olism disorders. However, the relationship between HCV
infection and lipid metabolism disorder among the SNPs
of these lipid regulators have not yet been fully eluci-
dated. Therefore, in this study, we first investigated the
relationship between the SNPs of lipid regulator genes
such as apolipoproteins and cell surface molecules that
affect the HCV life cycle, and HCV infection status
comparing HCV-positive and HCV-negative subjects.
We then examined differences in lipid metabolism be-
tween each SNP genotype and analyzed the causal rela-
tionship between the SNP and HCV infection status
through altered lipid metabolism.
Methods
Subjects
This study included a total of 378 subjects who visited
our university hospital and affiliated hospitals from
November 2010 to March 2014. All subjects were
Japanese and were between 41 and 76 years old. Patients
who had received prior or ongoing anti-viral therapy
and treatment for lipid metabolism disorders were ex-
cluded. We also excluded patients with inherited lipid
metabolism disorders such as familial hypercholesterol-
emia and secondary lipid metabolism disorders such as
hypothyroidism and kidney diseases.
An HCV antibody test was carried out for all subjects;
158 were HCV positive and HCV RNA detectable by
RT-PCR, and 220 were HCV negative. Serum HCV
RNA levels were measured using COBAS TaqMan HCV
Auto Assay System (Roche Diagnostics, Tokyo, Japan;
lower limit of quantification, 1.2 log IU/ml). HCV geno-
types were determined by direct sequence method at
BML, Inc. (Saitama, Japan). Serum transaminase, total
bilirubin, albumin levels, and prothrombin time were
measured, and ultrasonography or contrast-enhanced
computed tomography was performed to check liver
function and search for HCC. Based on these results,
subjects with severe liver dysfunction of Child-Pugh
class B and C were excluded from the study. Patients
with conditions associated with liver dysfunction such as
HCC, hepatitis B virus (HBV) infection, or nonalcoholic
steatohepatitis (NASH) were also excluded from the study.
The study protocol was approved by the institutional
review board of each hospital and all patients provided
written informed consent to participate in this study.
Measurement of serum lipids and apolipoproteins
Serum lipids and apolipoproteins were tested after fasting
overnight for 10 to 12 h. We measured low density
lipoprotein-cholesterol (LDL-C), high density lipoprotein-
cholesterol (HDL-C), and triglyceride (TG) according to
standard procedures at our university hospital and affili-
ated hospitals. Serum levels of apolipoproteins (apolipo-
protein A1 [APOA1], apolipoprotein A2 [APOA2],
APOB, apolipoprotein C2 [APOC2], apolipoprotein C3
[APOC3], and APOE) were measured by immune nephe-
lometry at SRL, Inc. (Tokyo, Japan).
SNP selection
We selected 22 SNPs in five genes (APOA1, APOB,
SR-B1, LDLR, and APOE) which are related to HCV
entry into hepatocytes and are associated with lipid me-
tabolism disorders according to previous studies; three
SNPs (rs613808, rs2727784, and rs11216158) in APOA1
[17], five SNPs (rs676210, rs1042031, rs693, rs1801701,
and rs1042034) in APOB [9], three SNPs (rs4238001,
rs61932577, and rs5888) in SR-B1 [10], nine SNPs
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(rs17249134, rs17249141, rs2228671, rs11669576,
rs5930, rs688, rs5925, rs2569542, and rs14158) in LDLR
[13], and two SNPs (rs429358 and rs7412) in APOE [18].
Genotyping
Genomic DNA was extracted from peripheral blood using
the phenol-chloroform method and stored at − 4 °C.
Genotypes of all SNPs selected in this study were analyzed
at G&G Science Co., Ltd. (Fukushima, Japan) using the
PCR-sequence-specific oligonucleotide probe-Luminex
method, as described previously [19].
Statistical analysis
Student’s t-test was used to compare serum lipid and
apolipoprotein levels between the two subject groups
(HCV-positive and HCV-negative) as well as the geno-
type groups for each SNP. The genotype distributions
for each SNP were analyzed using χ2 test. A P value of
less than 0.05 was considered statistically significant.
The statistical analyses were performed using Statcel 4
(OMS Ltd., Saitama, Japan). Linkage disequilibrium was
analyzed using the program Haploview from the Broad
Institute website (https://www.broadinstitute.org/haplo-
view/haploview).
Results
Characteristics of the subjects
The study included 158 patients with HCV infection and
220 subjects without HCV infection. The age and sex ratio
were well balanced between the groups. There was no sig-
nificant difference in serum total bilirubin, AST, ALT and
albumin levels, and prothrombin values (%), which are in-
dicative of hepatic functional reserve, and were also well
balanced between groups. HCV infected patients were
genotype 1b (n = 128), 2a (n = 5), 2b (n = 9), 3a (n = 1), and
undetermined (n = 6). The remaining nine patients
received only serotype analysis: serotype I (n = 7) and sero-
type II (n = 2).
Among 158 subjects with HCV infection, the
estimated median duration of HCV infection was 51
(IQR 44.3–55.0) years, and the median HCV RNA
concentration in HCV-infected patients was 6.5 (IQR
6.0–6.9) log IU/ml.
Profile of serum lipids and apolipoproteins in HCV-positive
and HCV-negative subjects
Since HCV infection reportedly causes a change in
serum lipid levels, we first compared the serum lipid
levels between 158 HCV-positive subjects and 220
HCV-negative subjects (Table 1). The serum levels of
total cholesterol (TC), LDL-C, and HDL-C in HCV-posi-
tive subjects were significantly lower than in HCV-
negative subjects, whereas the serum TG level in HCV-
positive subjects was higher than in HCV-negative
subjects, although the difference was not statistically
significant. Moreover, serum levels of all six apolipopro-
teins (APOA1, APOA2, APOB, APOC2, APOC3, and
APOE) in HCV-positive subjects were significantly lower
than in HCV-negative subjects. These results were fairly
consistent with previous reports [6, 20, 21].
Association of SNP genotype with HCV infection
To examine the relationship between SNP genotype in
lipid regulator genes and HCV infection status, we
analyzed the genotype distribution of the selected 22
SNPs in APOA1, APOB, SR-B1, LDLR, and APOE, and
compared them between HCV-positive and HCV-
negative groups (Table 2). Of the 22 SNPs examined, five
were monomorphic in our study population; rs1801701
in APOB; rs61932577 in SR-B1; rs17249134, rs17249141,
and rs11669576 in LDLR.
In the comparison of overall genotype distributions for
each SNP, an APOB N4311S (g.41553a > g) SNP,
rs1042034, showed a marginally non-significant trend
with respect to HCV positivity (P = 0.051, χ2 = 5.963);
the frequency of the A allele in HCV-positive subjects
was higher than in HCV-negative subjects. In the com-
parison of specific genotypes (GG +AG vs. AA), the
HCV positivity rate in the genotype AA group was sig-
nificantly higher than in the genotype GG +AG group
(P = 0.016, χ2 = 5.828). These results suggest that minor
allele homozygosity (genotype AA) in rs1042034 might
be associated with HCV infection. Moreover, an APOB
P2712L (g.35310c > t) SNP, rs676210, showed a similar
tendency to that of rs1042034; i.e., the frequency of the
genotype CC allele in rs676210 was significantly higher
than that of genotype TT + CT in HCV-positive subjects
(P = 0.031, χ2 = 4.673). Other SNPs aside from these two
showed no significant difference in genotype distribution
between HCV-positive and HCV-negative subjects.
Table 1 Profile of serum lipids and apolipoproteins in HCV-positive
and HCV-negative subjects
Normal range HCV+ HCV- P-value
TC (mg/dl) 120.0–219.0 169.4 ± 31.3 207.2 ± 32.0 < 0.001
LDL-C (mg/dl) 65.0–139.0 96.8 ± 24.3 124.8 ± 29.5 < 0.001
HDL-C (mg/dl) 40.0–90.0 53.1 ± 18.5 62.9 ± 17.6 < 0.001
TG (mg/dl) 30.0–149.0 106.6 ± 52.2 98.3 ± 56.6 0.173
APOA1 (mg/dl) 120.0–160.0 139.6 ± 31.3 155.2 ± 29.2 < 0.001
APOA2 (mg/dl) 25.0–34.6 29.6 ± 5.5 30.8 ± 4.9 0.022
APOB (mg/dl) 70.0–106.0 77.2 ± 17.9 96.7 ± 22.8 < 0.001
APOC2 (mg/dl) 1.6–4.2 2.1 ± 1.0 4.0 ± 1.7 < 0.001
APOC3 (mg/dl) 5.6–9.5 6.0 ± 2.3 9.2 ± 3.1 < 0.001
APOE (mg/dl) 2.7–4.5 4.4 ± 1.1 4.7 ± 1.2 0.011
Data represent mean and standard deviation values and P-values were
calculated using Student’s t-test
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Table 2 Association of SNP genotype with HCV infection
Alleles HCV Overall genotype
distribution(n)
P-value Comparison of
specific genotypes
P-value
(χ2 value) (χ2 value)
APOA1 rs613808 G/A AA GA GG
+ 72 74 12 0.192
– 120 83 17 (3.297)
rs2727784 G/A GG GA AA
+ 75 71 12 0.290
– 122 82 16 (2.473)
rs11216158 A/G GG AG AA
+ 99 56 3 0.231
– 150 62 8 (2.933)
APOB rs676210 C/T TT CT CC
+ 88 57 13 0.091 TT + CT vs CC 0.031
– 133 80 7 (4.784) (4.673)
rs1042031 G/A GG GA AA
+ 150 8 0
– 205 15 0
rs693 C/T CC CT TT
+ 147 11 0
– 199 21 0
rs1801701 G/A GG GA AA
+ 158 0 0
– 220 0 0
rs1042034 A/G GG AG AA
+ 88 57 13 0.051 GG + AG vs AA 0.016
– 134 80 6 (5.963) (5.828)
SR-B1 rs4238001 G/A GG GA AA
+ 157 1 0
– 220 0 0
rs61932577 C/T CC CT TT
+ 158 0 0
– 220 0 0
rs5888 C/T CC CT TT
+ 96 54 10 0.761
– 128 82 10 (0.546)
LDLR rs17249134 T/G GG TG TT
+ 158 0 0
– 220 0 0
rs17249141 T/C CC TC TT
+ 158 0 0
– 220 0 0
rs2228671 C/T CC CT TT
+ 156 2 0
– 219 1 0
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The rs1042034 SNP is located at the APOB carboxyl-
terminal site, 6243 nucleotides away from rs676210, and
this is reportedly in strong linkage disequilibrium [9]. The
degree of linkage disequilibrium between these SNPs in
our study population was also strong (D’ = 1, r2 = 0.98).
Therefore, we confined the following association analysis
of these SNPs with serum lipids only to rs1042034.
Association of serum lipid and apolipoprotein levels with
the rs1042034 genotype
Since APOB is reported to be associated with serum
lipid levels [9], we compared the serum lipid levels
between genotypes AA and non-AA (GG + AG) in
rs1042034 (Table 3). The serum LDL-C level in the
genotype AA group was significantly lower than that in
the genotype non-AA group (98.7 ± 39.4 vs. 115.1 ± 30.1,
P = 0.032), whereas the TG level was significantly higher
in the genotype AA group than in the genotype non-AA
group (137.7 ± 67.7 vs. 100.7 ± 55.3, P = 0.007). There
were no significant differences in serum levels of
APOA1, APOA2, APOB, APOC2, APOC3, and APOE.
Table 2 Association of SNP genotype with HCV infection (Continued)
Alleles HCV Overall genotype
distribution(n)
P-value Comparison of
specific genotypes
P-value
(χ2 value) (χ2 value)
rs11669576 A/G GG AG AA
+ 158 0 0
– 220 0 0
rs5930 G/A GG GA AA
+ 66 73 19 0.957
– 89 105 26 (0.088)
rs688 T/C CC TC TT
+ 120 36 2 0.664
– 160 55 5 (0.820)
rs5925 C/T TT CT CC
+ 114 42 2 0.479
– 149 65 6 (1.472)
rs2569542 A/G GG AG AA
+ 138 19 1 0.935
– 190 28 2 (0.135)
rs14158 G/A GG GA AA
+ 58 75 25 0.928
– 84 100 36 (0.150)
APOE rs429358 T/C TT TC CC
+ 131 27 0 0.564
– 177 41 2 (0.333)
rs7412 C/T CC CT TT
+ 142 16 0
– 196 24 0
Table 3 Association of serum lipid and apolipoprotein levels
with the rs1042034 genotype
Genotype of rs1042034 P-value
AA (n) GG + AG (n)
TC (mg/dl) 176.7 ± 46.5 (17) 191.8 ± 36.2 (332) 0.100
LDL-C (mg/dl) 98.7 ± 39.4 (17) 115.1 ± 30.1 (316) 0.032
HDL-C (mg/dl) 50.8 ± 19.4 (15) 59.6 ± 18.4 (302) 0.074
TG (mg/dl) 137.7 ± 67.7 (18) 100.7 ± 55.3 (321) 0.007
APOA1 (mg/dl) 137.5 ± 34.1 (19) 149.3 ± 30.9 (355) 0.105
APOA2 (mg/dl) 29.6 ± 4.9 (19) 30.4 ± 5.2 (355) 0.547
APOB (mg/dl) 83.6 ± 29.5 (19) 88.9 ± 22.6 (355) 0.335
APOC2 (mg/dl) 3.2 ± 1.9 (19) 3.2 ± 1.7 (355) 0.945
APOC3 (mg/dl) 7.9 ± 3.6 (19) 7.9 ± 3.2 (355) 0.975
APOE (mg/dl) 4.8 ± 1.9 (19) 4.5 ± 1.1 (355) 0.390
Values are expressed as mean± standard deviation. The number of subjects available
for the analysis is shown in parentheses. P-values were calculated using Student’s t-test
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To assess the effect of HCV status on lipid levels, we
compared serum lipid and apolipoprotein levels between
AA and non-AA genotypes of rs1042034 in HCV-posi-
tive and HCV-negative subjects (Table 4). No significant
differences were observed in the levels of
apolipoproteins between the AA and non-AA groups re-
gardless of HCV status.
Discussion
In this study, we demonstrated that the AA genotype of
rs1042034 in the APOB gene is significantly related to
HCV infection status and might be associated with the
regulation of serum LDL-C and TG levels. These re-
sults could suggest a close association between HCV
infection status and lipid metabolism alterations due to
the APOB SNP.
HCV exists in blood as an LVP, with which APOB and
APOE are also combined [22]. HCV in LVPs can enter
into hepatocytes through LDLRs on the cell membrane
[23]. APOB-100 is deeply involved in these steps as a
ligand for the LDLR; however, the underlying mecha-
nisms have not yet been clarified in detail [24].
Previously, Li and colleagues reported that an SNP in
LDLR exon 13 (rs5925) was associated with susceptibility
to HCV infection [12], but we did not detect a signifi-
cant difference in the SNP in our cohort. This difference
may be due to the fact that the previous study involved
a smaller subject cohort (a total of 156 subjects) as com-
pared with our study (378 subjects). Zhu and associates
reported that an SNP in the APOB promoter region
(rs934197) was associated with susceptibility to HCV
infection, and showed that HCV-infected patients had
significantly lower levels of LDL-C as compared with
healthy individuals [25]. Although we did not analyze
SNPs in the promoter region, a similar tendency of
lower LDL-C levels was observed; HCV-positive subjects
with AA genotype of APOB exhibited lower LDL-C
levels than the other genotypes. Moreover, rs1042034 in
APOB is known to regulate biding to the LDLR and is
therefore assumed to cause a change in the binding af-
finity of APOB to LDLRs [26]. These findings are further
supportive of a close relationship between the life cycle
of HCV and host APOB polymorphism.
Since serum lipid levels are very important risk factors
for cardiovascular disease, several large-scale screenings
for SNPs concerning serum lipid-regulator genes have
been reported. Regarding studies of the APOB SNP
rs1042034, the genome-wide association study (GWAS),
which included more than 100,000 individuals of
European ancestry, reported that polymorphism of
rs1042034 was significantly associated with decreased TG
and increased HDL-C levels [27]. In a study involving sev-
eral ethnic groups, rs1042034 was significantly associated
with lower TC and LDL-C levels only in Hispanics [28].
As for Asians, rs1042034 was significantly associated with
lower TG and higher HDL-C levels in South Asians, com-
patible with the European GWAS, but there was no sig-
nificant association in East Asians [27]. Although the
underlying mechanism of the changes in serum lipid levels
caused by this SNP have still not been elucidated, it
appears APOB-100 mutations and polymorphisms may
change the conformation of APOB-100, thereby leading to
a change in LDL metabolism through the interaction of
APOB-100 with the LDLR.
Based on the findings mentioned above, we can specu-
late that a relationship exists between HCV infection
and lipid metabolism disorders through SNPs of APOB-
100, whereby the AA genotype (minor allele homozy-
gote) of rs1042034 could facilitate serum LDL uptake via
LDLR on hepatocytes by modifying their mutual affinity
and interaction, and consequently, the serum LDL-C
level could be decreased. As a result, the susceptibility to
HCV infection could be increased because HCV parti-
cles exist as LVPs and enter into the liver with LDL.
However, it is not clear why genotype AA was associated
with higher serum TG levels as compared with genotype
Table 4 Associations of serum lipid and apolipoprotein levels with
rs1042034 genotype in HCV-positive and HCV-negative subjects
HCV Genotype of rs1042034 P-value
AA (n) GG + AG (n)
TC (mg/dl) + 160.9 ± 43.5 (11) 170.3 ± 30.1 (138) 0.342
– 205.7 ± 39.7 (6) 207.1 ± 32.0 (194) 0.917
LDL-C (mg/dl) + 86.2 ± 31.9 (11) 97.7 ± 23.2 (114) 0.134
– 121.5 ± 44.4 (6) 124.9 ± 29.1 (202) 0.779
HDL-C (mg/dl) + 47.1 ± 22.6 (9) 53.6 ± 18.2 (110) 0.313
– 56.5 ± 13.1 (6) 63.1 ± 17.7 (192) 0.370
TG (mg/dl) + 135.3 ± 66.1 (12) 106.3 ± 54.8 (127) 0.088
– 142.5 ± 31.5 (6) 97.0 ± 55.4 (194) 0.052
APOA1 (mg/dl) + 130.6 ± 35.8 (13) 140.5 ± 31.1 (144) 0.278
– 152.3 ± 27.0 (6) 155.3 ± 29.3 (211) 0.805
APOA2 (mg/dl) + 29.9 ± 5.6 (13) 29.6 ± 5.5 (144) 0.868
– 29.1 ± 3.5 (6) 30.9 ± 4.9 (211) 0.374
APOB (mg/dl) + 74.1 ± 21.8 (13) 77.7 ± 17.6 (144) 0.490
– 104.3 ± 35.3 (6) 96.5 ± 22.4 (211) 0.407
APOC2 (mg/dl) + 2.6 ± 1.3 (13) 2.1 ± 1.0 (144) 0.056
– 4.5 ± 2.6 (6) 4.0 ± 1.6 (211) 0.505
APOC3 (mg/dl) + 6.6 ± 2.7 (13) 6.0 ± 2.3 (144) 0.394
– 10.7 ± 3.9 (6) 9.1 ± 3.0 (211) 0.210
APOE (mg/dl) + 4.8 ± 2.0 (13) 4.3 ± 1.0 (144) 0.114
– 4.7 ± 1.7 (6) 4.7 ± 1.2 (211) 0.979
Values are presented as mean ± standard deviation. The number of subjects
available for the analysis is shown in parentheses. P-values were calculated
using Student‘s t-test
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non-AA, and further studies are needed to investigate
this relationship in greater detail.
In the comparison of lipid levels by genotype, serum
levels of LDL-C and TG showed significant differences
between AA and non-AA genotype (Table 3), whereas
these differences disappeared when comparing by HCV
status (Table 4), indicating that HCV infection itself did
not have much influence on lipid metabolism, which
supports our hypothesis.
Interestingly, a large Japanese cohort study revealed
that HCV infection causes not only lower TC and
LDL-C levels but also significant lower serum HDL-C
and TG levels [21] and they suggest that the HCV infec-
tion itself might directly cause hypolipidemia, irrespect-
ive of host factors including age, hepatic damage, and
nutritional state. Furthermore, it has been reported that
HCV genotype 3a and 4 are associated with hypocholes-
terolemia in western patients [29, 30]. However, there
was no association between HCV genotypes and lipid
profile or SNP pattern in our cohort (data not shown).
This may be partly explained by the fact that the most
frequent genotype was 1b (81%), which is the most
common genotype in the Japanese population, while ge-
notypes 3a and 4 are very rare.
Therefore, the possibility of a direct interaction of
HCV with lipid metabolism could not be completely
ruled out in our study and need to be confirmed in a
more detailed investigation.
There are some potential limitations of our study.
First, regarding the HCV negative cohort, we could not
completely rule out the possibility of including individ-
uals in whom HCV had been eradicated naturally
because we enrolled subjects who were negative for
serum anti-HCV antibody. Second, the lipid metabolism
profiles could have been altered by differences in liver
function, which can be affected by various hepatic disor-
ders. However, in the present study, we carefully limited
the participants to Child-Pugh A, and excluded subjects
with NASH, HBV infection, or HCC, and therefore the
baseline characteristics and liver function levels of the
participants were well balanced between the two groups.
Although our study had a limitation in terms of not
covering all SNPs in lipid regulators, our results sug-
gested the possibility that an APOB-100 SNP, rs1042034,
influences the susceptibility to HCV infection by their
entry into the liver through the LDLR. Our data may
have important implications for identifying individuals
with higher susceptibility to HCV infection via SNP of
lipid regulators. Exploring the molecular mechanism
underlying these results could provide important infor-
mation for controlling the process of HCV infection and
limiting the expansion of HCV infection.
In addition, in the treatment of chronic HCV infec-
tion, the rate of sustained virological response (SVR)
subsequent to the approval of direct-acting antiviral
agents has been dramatically increasing and the change
in serum lipid levels after SVR is gaining attention [31].
Therefore, focusing on the influence of SNPs concerning
lipid metabolism in HCV patients should have important
implications for antivirus therapy in the future.
Conclusions
In conclusion, this study demonstrated that an APOB
SNP, rs1042034, is closely associated with HCV infection
through lipid metabolism alteration. The minor allele
AA genotype may facilitate serum LDL uptake into
hepatocytes via LDLR by modifying their affinity and
interaction and may have an influence on HCV infection
by their entry into the liver through the LDLR. Further
studies are needed to explore the mechanism underlying
these results, which could provide important informa-
tion for controlling the process of HCV infection.
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